Updated
OnKure TherapeuticsOKUR · Healthcare
$3.12-2.04%
Market cap$127M
IndustryBiotechnology
OnKure Therapeutics (OKUR) Financial statements
Net income was -$60M.
Key figures
Free cash flow was -$52M. The diluted share count rose 6564% over the period (dilution).
- Revenue, FY2025
- —
- Net income
- -$60M+13.0% on 2024
- Operating margin
- —
- Free cash flow
- -$52M+1.4% on 2024
Revenue and free cash flow
Fiscal years, from OnKure Therapeutics's 10-K filings.
OnKure Therapeutics revenue and free cash flow
FY2020–FY2025OKURFree cash flow-$52M
Financial statements
Fiscal 2020–2025.
OnKure Therapeutics income statement, fiscal 2020–2025
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 | — |
| Research and development | $16M | $28M | $38M | $32M | $44M | $48M |
| Selling, general and admin | $4M | $12M | $16M | $5M | $11M | $15M |
| Operating income | -$20M | -$40M | -$54M | -$37M | -$54M | -$63M |
| Pre-tax income | -$19M | -$40M | -$52M | -$77M | -$53M | -$60M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$19M | -$40M | -$52M | -$35M | -$53M | -$60M |
| EPS (diluted) | -$96.00 | -$21.90 | -$21.20 | -$124.41 | -$15.28 | -$4.40 |
| Diluted shares | 0M | 2M | 2M | 0M | 3M | 14M |
OnKure Therapeutics balance sheet, fiscal 2020–2025
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $54M | $148M | $101M | $105M | $111M | $59M |
| Total current assets | $55M | $154M | $106M | $34M | $113M | $61M |
| Property, plant and equipment | $69,000 | $212,000 | $453,000 | $1M | $1M | $618,000 |
| Total assets | $55M | $154M | $108M | $36M | $115M | $62M |
| Total current liabilities | $5M | $6M | $7M | $7M | $11M | $6M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Total liabilities | $5M | $7M | $8M | $8M | $11M | $6M |
| Shareholders' equity | -$42M | $147M | -$54M | -$102M | $104M | $56M |
| Net debt | -$54M | -$125M | -$20M | -$30M | -$111M | -$59M |
OnKure Therapeutics cash flow, fiscal 2020–2025
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$19M | -$38M | -$47M | -$35M | -$51M | -$52M |
| Capital spending | $24,000 | $198,000 | $346,000 | $246,000 | $52,000 | $46,000 |
| Free cash flow | -$19M | -$38M | -$48M | -$35M | -$51M | -$52M |
| Stock-based compensation | $393,000 | $4M | $4M | $199,000 | $5M | $12M |
| Share buybacks (net) | — | — | — | -$4M | — | — |
How OnKure Therapeutics compares
OnKure Therapeutics's ROE is higher than 32% of Healthcare companies and 11% of the 3,458 companies with an ROE figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| ROE | 32% | 11% |
Questions about OnKure Therapeutics
How much free cash flow does OnKure Therapeutics generate?
-$52M in fiscal 2025 (operating cash flow minus capital spending).
From OnKure Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.